Skip to content
LEARN MORE ABOUT KEYNOTE 695
About
About
Join The Team
Management Team
Pipeline
Technology
Technology
Tavo
VLA
Combination Approach
Publications
Partnering
Patients
Patients
Resources
Expanded Access
Together Against Cancer
Investors
Media & Videos
Contact
Menu Toggle
About
Menu Toggle
About
Join The Team
Management Team
Pipeline
Technology
Menu Toggle
Technology
Tavo
VLA
Combination Approach
Publications
Partnering
Patients
Menu Toggle
Patients
Resources
Expanded Access
Together Against Cancer
Investors
Media & Videos
Contact
MEDIA
Media Inquiries
Investors@OncoSec.com
855-662-6732
Press Releases
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
June 24, 2022
OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research
May 23, 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
April 29, 2022
VIEW ALL PRESS RELEASES
Video Feed
3D MOA Animation video
✕
OncoSec's VLA 3D MOA Animation
✕
TAVO Demonstration with Dr Algazi
✕
OncoSec at 2020 BIO CEO Panel
✕
Tumor Immunogenicity
✕
IAD Reel
✕
IAD Robert Andtbacka, M.D.
✕
Social Media
Twitter Feed
Featured Articles
Melanoma Research Alliance
From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate
PharmaVoice
Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter
Annals of Oncology
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
Clinical Cancer Research
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.